



YORK AGAINST CANCER

**A company limited by guarantee
and
A registered charity number 1130835**

REPORT AND ACCOUNTS

For the year ended

31 December 2023

**HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ**

YORK AGAINST CANCER

CONTENTS

	Page
Chairman's Report	1
Trustees' Report	2 - 18
Auditor's Report	19 – 22
Statement of Financial Activities	23
Balance Sheet	24
Cash Flow Statement	25
Notes to the Financial Statements	26 - 36

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2023

2023 saw the Charity continue to provide the vital and valuable support that makes it so unique. A number of projects progressed and the important £680,000 donation to the York and Scarborough Hospitals NHS Foundation Trust to enable it to acquire a new robotic surgical system, has proven to be an important investment in helping not only local cancer patients, but also helping the Hospital Trust ensure that more cancer expertise can be retained closer to home.

The cancer support centre, The Leveson Centre - named after one of the Charity's founders Professor Steve Leveson - was completed and has quickly become a very important part of what the Charity strives to provide. It is now our most visible location and delivers a wide range of services for those affected by cancer.

The mini-bus continues to offer a vital service to many who need to travel to Leeds for radiotherapy treatment, while the respite home at Filey remains a haven for those able to use it. The Filey property has recently been supplemented by a smaller property at Yapham which is just outside Pocklington and we would like to thank Phil and Hazel Arnold for their very generous support which allows more people to benefit from that important 'time away'. The Jack Birch Unit at York University continues to provide internationally recognised research into cancers, research which remains an important part of what York Against Cancer is all about.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

Our small office and retail team, our mini-bus drivers, the Leveson Centre team and our army of volunteers continue their hard work week to week, and to them, and Board colleagues, I would like to pass on my grateful thanks for your continuing support and promotion of the Charity.

With the completion of the Leveson Centre our longer-term commitments are now significant, and the need to look forward and plan for our current and future funding requirements goes on to ensure we remain focused and able to fund the important services for people impacted by cancer.

It is now 36 years since York Against Cancer was created. Its longevity is very much down to the vision of those who established the Charity all those years ago, but it is also a testament to the work undertaken by everybody who is or has been involved over the years.

Ian Yeowart
Chair York Against Cancer

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2023.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding and the provision of services and resources for patients and their families
- funding of research programmes
- funding of education initiatives

Achievements and performance

The Office Team

The office team have settled into their new working environment within York Stadium and are building business relationships with other key stakeholders. They continue to deal with the complex operational challenges that arise, and they do this with great resolve and in a positive manner. Each member of the team has their own responsibilities; however, they support each other with day-to-day tasks, ensuring the smooth operation of the charity and everyone receives the support they need. They respond quickly to any requests and challenges they are faced with, and this is recognised as a key strength of the team.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023


Care group report 2023

The purpose of the Care group is to consider applications both external and internal for “care” projects to be funded by York Against Cancer and to make recommendations to the Board of Trustees for ratification.

The group comprises of YAC Trustees and representatives from different areas of the charity, who have the expertise to make judgements on the value of the proposed projects.

There is a stringent application process which is adhered to; a standard application form is used and the following pathway.

Pathway for applications for funding or new ventures from YAC.



19/08/2019

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Not all applications are successful but the ones that are, must show clear evidence that the project is of value to patients, has longevity and fulfils the over-arching aims of the charity.

Please see below a list of successful projects funded in 2023.

- The Leveson Centre
- Transport to Rapid Diagnostic Appointments
- Adult & Teenage Psychology Support
- Cancer Prehabilitation project, Selby
- Da Vinci Surgical Robot
- Cancer Benefits Advice Service – Scarborough (continuation) **
- Cancer Benefits Advice Service – York (new) **

** Some projects have a fixed term contract, (usually 2 or 3 years) these are be reassessed before being renewed or otherwise.

This robust approach for the consideration of funding care projects shows due diligence given to the spending of money which has been donated or fundraised for by the general public.

I would like to thank my colleagues who sit on the Care group for their time and hard work during 2023.

Mike Stower

Chair of the Care group

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

SUPPORT AND CARE SERVICE ACTIVITIES

Services and posts supported by York Against Cancer

In addition to the team directly employed by the charity there are other support workers whose salary costs are paid by York Against Cancer. These posts are as follows, which illustrates the range of activities supported by the Board:

- **Cancer Benefits Advice Service – Scarborough (in collaboration with Citizens Advice North Yorkshire)**

The charity continues to fund a cancer benefits advice service providing holistic financial advice for cancer patients in the Scarborough area: ensuring they receive the financial help to which they are entitled.

The main issues faced by clients by proportion are shown as follows: -

ISSUE – Patients Concerns	2022-23	2021-2022
· Benefits	97%	97%
· Charitable applications	28.5%	15%
· Health & Community Care	5%	5%
· Debt	2%	2%
· Financial services	3.5%	4%
· Employment	1.5%	2%
· Housing	2%	5%
· Travel & Transport	5%	6%

As demonstrated by these figures the issue of Benefits remains at the top of the agenda, affecting 97% of clients.

During 2023 the majority (77%) of clients were aged between 55 and 84 years old; although, 14% of our clients were under 55 and 9% aged 85 or over.

Pressures of the escalating cost of living directly impact cancer patients as they fall into the most vulnerable of categories and as a result there was a substantial increase in the need for charitable support and food banks. The number of clients requiring this type of assistance for the previous year was 70, this year the number has more than doubled to 160.

- **Cancer Benefits Advice Service – York (in collaboration with Citizens Advice North Yorkshire)**

An agreement was signed in October 2023 for the York service and a full report will be available for the 2024 annual report.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

- **Teenage Psychology Support**

YAC funds Dr Rebecca Donaldson, a Teenage Psychologist who supports young people when they or someone they know is affected by cancer. This service is funded on a need basis, during 2023 the charity spent £16k on this service. Referrals are received from Clinical Nurse Specialists, Oncologists, G.P's and the Leveson Centre. Dr Donaldson (Becky) is often accompanied by her Therapy dog, Luna.



- **Adult Psychology**

Dr Jo McVey, Adult Psychologist started seeing patients in October 2023 in the Leveson Centre, a full report will be available for the 2024 annual report.

Mobile Chemotherapy Unit



The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients avoid the time-consuming and tiring journeys to the hospital in York. During 2023 we continued to fund the cost of servicing and repairs to keep the MCU on the road.

Minibus

Our minibus service continues to be popular; we provide free transport for patients going to St James hospital in Leeds for radiotherapy treatments. During 2023 we provided 73 individual patients with transport to Leeds – radiotherapy is given daily (Mon-Fri) and length of treatments can range from 3 to 7 weeks. If the demand is high we use volunteer drivers and if demand is low, we use the YAC car, making the service more efficient.



DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

'Just to say thank you. The bus to Leeds was a God send. It was good fun with the people on the bus.'

'Thank you for your kindness and help getting to St James hospital.'

The provision of patient transport to Rapid Diagnostic appointments.

We work closely with the Rapid Diagnostic department offering transport to patients who need to get to their diagnostic appointments which are not always at their nearest hospital.


We have provided transport to these types of appointments since 2021 and in the last 12 months have helped 29 patients from York, Malton and Scarborough at a cost of £2900 p.a.

Respite Properties


Our Filey house provides valuable respite breaks for cancer patients; during 2023 156 patients visited the property along with family or friends.

In April, local couple Hazel and Phil Arnold completed a full renovation of one of their farm buildings, situated in Yapham, which is 4 miles from Pocklington. They have offered us full use of their property as a second respite offering. The cottage sleeps 2 people and is a valuable addition to the Filey house.

We encourage feedback from service users to ensure we get to know of any issues and so we can keep the standards high. If any improvements need addressing, we act on these quickly. On booking a break we ask for a deposit; visitors can request this be returned but many users donate it to us as a way of a thank you.



Thank you so much, our stay in Filey was wonderful and beyond our expectations.



Thank you for all you do for cancer patients. We had an amazing break and will treasure all the memories.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Leveson Centre – providing cancer support services

On 6th February 2023 the doors of the Leveson Centre opened providing cancer patients, their friends and family somewhere to access support, care and information whilst going through cancer. The 'look and feel' of the Centre was intentionally non-clinical, the space is welcoming, friendly, calming, and inclusive.

The footfall during 2023 went from 173 visitors in its first month to over 600 per month by the end of the year. We record how many patients, family members, friends and hospital professionals visit each day and record whether the visit is a planned appointment or a walk-in. This information provides the data to ensure we have our staffing and volunteer numbers correct.

A range of activities are on offer in the Centre, this has grown gradually during 2023. We listen to visitors' feedback and have grown our activity accordingly.

- Complementary Therapy
- Arts and Crafts workshop
- Weekly coffee mornings
- Nicola Jane, bra fitting & advice
- Family and friends support groups
- Head covering design project
- Relaxation classes
- Well-being Choir
- Look good feel better
- Pilates
- Welfare Benefits Service

Also, Psychology appointments are available at the Leveson Centre as detailed on page 3 of this report.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

RESEARCH ACTIVITIES

Clinical Research Nurse and Assistant posts at York Hospital

During 2023 funding support to clinical trials has enabled four new studies, including Haematology, Colorectal, Breast and early cancer detection. There were eleven cancer studies open, seven of these hit the target number of recruits which would not have been achieved without the YAC funding.

The funding was also instrumental in the continuation of the PINPOINT Study. This study is a simple blood test, which seeks to become another tool in primary care to triage those who are being considered for the two-week wait cancer pathway. This study works in collaboration with GPs and the Rapid Diagnostic Centre, it uses biomarkers in the blood to provide a 'Pinpoint score'. The study recruited 664 participants (as of 9/11/23) of which 41 were found to have cancer.

Our funding continues to provide essential support to many of the long-standing studies, many of which continue above and beyond 10+ years.

Jack Birch Unit (University of York)

The Charity is committed to another 9 months supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis – Annual Report 2023

York Against Cancer provides funds in the form of a generous five-year programme grant to support research in the Jack Birch Unit, where we have built unique expertise in urothelial (bladder) cancer research. Although one of the top 10 common cancers of ageing, bladder cancer typically receives less research funding than other cancers. This means that York Against Cancer's funding is able to make particular research impact.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

One important aspect of our work in the JBU is the training of the next generation of scientists and it has been a timely year to mark the significant progress being made by two of JBU's outstanding researchers, Dr Simon Baker and Dr Andrew Mason, as they nurture their own research groups within the JBU. A reorganisation of the [JBU website](#)* was carried out to reflect their changing status as group leaders. Simon holds a fellowship from Kidney Research UK and is studying a common virus as a possible cause of bladder cancer. Andrew, who was originally appointed to the YAC 30th Anniversary Fellowship, now holds a lectureship and studies data collected from urothelial cancers in the UK and worldwide. Indeed, Andrew is himself now involved in training the next generation of students in cancer informatics, with two of his group receiving prizes at one of the scientific meetings attended. Under other staff news, Dr Jenny Baker (née Hinley) who had studied her PhD in the JBU, rejoined after a stint away and Denise Alaniz Barraza from Mexico joined the group for 12 weeks' research experience after completing her Master's degree in the Department of Biology. Our YAC-funded PhD student, Ryan Ellison left towards the end of the year to write up his thesis and was replaced by George Hatton, who prior to becoming the new YAC PhD student, completed his final year project in the JBU as part of his Integrated Master's degree.



Tea Party for YAC supporters in the Guildhall.

One of the year's highlights occurred in March, when Ian Yeowart and Julie Russell visited the University to meet the Vice Chancellor. Professor Charlie Jeffrey thanked York Against Cancer for their ongoing support of the Jack Birch Unit and discussed future opportunities for partnership with the University under the 2030 vision of a "University for Public Good". This was followed by a series of research presentations in the JBU. Later, in April, a tea party was held at the Guildhall in York to celebrate YAC's induction into the University's College of Benefactors and to thank YAC supporters and fundraisers for the fantastic job they do.

Finally, as JBU Director, I would like to thank York Against Cancer Trustees, fundraisers and supporters for the research support we receive. I further thank all our scientific and clinical collaborators for the important contribution they make to the quality and output of our research.

**Professor Jenny Southgate, Director,
Jack Birch Unit of Molecular Carcinogenesis, University of York**

* <https://www.york.ac.uk/biology/jack-birch-unit/>

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2023

Our committed team has continued to meet regularly, either face to face or via zoom.

Dr Simon Baker, Research Scientist at the Jack Birch Unit, has taken the lead with the Enthuse partnership project, working with the National STEM Learning Centre (NSLC) and 6 local secondary schools (spreading out from the city to include Selby and Malton). The partnership aims to train teachers to be more confident in teaching cancer-related topics and a cancer-focussed programme of continuing professional development has been delivered by the NSLC over the last two years. The partnership has engaged Amazelab who develop engaging, creative teaching resources relating to DNA and cell biology which have received very positive reviews from the schools.

Another key feature of the project is to teach young people about cancer research using practical experiments with scientists from the Jack Birch Unit in the state-of-the-art University of York teaching laboratories. We have taken students from three schools through a DNA mutation practical in the labs followed by bioinformatics work package created by Dr Andrew Mason. Again, the new practical designed around a specific cancer-causing mutation in the p53 gene was very well received.

We are now looking to cherry-pick the best bits of our Enthuse partnership and develop an ambitious new phase of this project aiming to reach more schools for even more impact. Every teacher we reach can influence hundreds of students and their families.

We have distributed 1300 sun hats to 37 primary schools in the York and surrounding area. Our committed volunteers helped with the delivery to the participating schools.

Before Covid we provided Primary schools with books about how to talk to children about cancer, they were popular and after seeking feedback from the schools, the A & E group plan to repeat this project but with new and up to date books.

We held an awareness day in York City Centre in October, this gave us the opportunity to talk to people about cancer awareness and about the work of the charity.

As always, the priority of the group is to ensure making the biggest difference with our limited resource. Our focus has been to look at local cancer screening uptakes and to compare with the national statistics. This year we looked specifically at bowel cancer screening as it was deemed this screening could be improved upon in Yorkshire. A drinks mat was designed and handed out at events which included the awareness day.

The group is also looking at the local geography and underrepresented groups comparing cancer statistics looking for areas which need our focus. We have contacts within the clinical commissioning group from whom we can get the detailed data on which we can act on in the future.

We are looking at widening our reach across the whole of York and North and East of Yorkshire in collaboration with the communications committee.

Thank you to the YAC team and the Awareness and Education group members.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2023 in relation to its fundraising activities.

Fundraising report 2023

We have again been very lucky with the fundraising support we have received from individuals, businesses, organisations, and groups in the last 12 months.

As well as holding our own events at which we have been supported brilliantly by our volunteers, there are events that are organised on our behalf. On many occasions the first we know about an event is when we see an amount of money come into the bank account or we are handed a cheque. Every pound received helps us to continue with services we already provide and to plan what we may do more to help, support and care for cancer patients. We really cannot do what we do without the support of fundraising.

Here are a few of our events and the fantastic amounts raised.

- The Three Bears Charity – Three Peak Challenge - £16,000
- YDL – Twelve Peak Challenge – £1,500
- Stamford Bridge Community Choir – £11,000
- York Rocks Christmas Against Cancer – £16,000
- Annual Golf Day - £16,500
- Jane Tomlinson 10k Run – £5,000
- Weighton Wolds Rotary Club – Classic Car show - £4,500
- Christmas Lunch – £1,500
- Charity of the Year – Hiscox Insurance - £3,300
- Charity of the Year – Deans Garden Centre - £10,000

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

When we are talking to prospective fundraisers, we like to tell them how the money they raise will be spent. The following graphic is used for this purpose.



FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to Chief Executive Officer with assistance from a Board member, Tarnia Hudson, who serves as the Honorary Administrator.

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the Chief Executive Officer.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and policies

The Charity's funds in 2023 decreased by £336,178 (2022 - decreased by £380,991). Prior to any adjustment for investments, the Charity made a deficit of £329,816 (2022 – deficit of £351,405). The largest new commitment in the year was £160,000 for the expansion of the Cancer Benefit Advice Service into the York Area.

The detail of funding of services and care activities can be found in note 6.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2023 amounted to £763,604 (2022 £1,468,175). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2023. Funds not invested are held on deposit to earn interest.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2023, before fees, was 3.27% (2022 -7.53%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2023, before fees, was -6.6% (2022 7.4%).

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2023 are £4,060,891 (2022 £4,397,069).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,093,281 (2022 £1,151,686). The level of free reserves is £697,568 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 12 months of our budgeted undesignated operating costs. It is the charity's policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £2,852,276 (2022 £3,109,980) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £115,334 (2022 £135,403) details of which are given in Note 17 to the financial statements.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

Approved by the Board on 6 August 2024 and signed on its behalf by:

Ian Yeowart
Director and Trustee

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Reference and administrative details

Registered Charity	number 1130835	Company Limited by Guarantee	number 06884476
Principal Office and Trading Address		East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF	
Company Secretary	Julie Pamela Russell		
Directors and Trustees	Andrew Proctor Angela Darby Rachel Goddard Michael John Stower Ian Yeowart Sarah Wearing	Dr Lynn Bartram (resigned 11 July 2023) Michael Sweet Robert Onyett Tarnia Hudson Prof Stephen Leveson Michael Patrick Shepherd (resigned 25 October 2023) William Mark Sessions (resigned 11 July 2023)	
	Trustee’s protocol available on request		
Accountants	HPH Chartered Accountants 54 Bootham York YO30 7XZ	Auditors	Henton & Co LLP Chartered Accountants 124 Acomb Road Holgate York YO24 4EY
Bankers	National Westminster Bank 1 Market Street York YO1 8SR	Solicitors	Harrowells Moorgate House Clifton Moorgate York YO30 4WY
Investment Advisors	HSBC Global Asset Management 78 St James’s Street London SW1A 1EJ		Ruffer LLP 80 Victoria Street London SW1E 5JL

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2023**

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2023 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2023 and of the groups incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2023**

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report have been prepared in accordance with applicable legal requirements.

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2023**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

- We have obtained an understanding of the legal and regulatory framework applicable to the group and parent charitable company through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the charitable company is a part of. The charitable company uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the company remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the group and charitable company; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the group's and charitable company's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2023.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the group's and charitable company's controls, and the nature, timing and extend of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2023

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's and charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....
Brett Davis (Senior Statutory Auditor)

For and on behalf of Henton & Co LLP

Chartered Accountants

Statutory Auditor

124 Acomb Road

York

YO24 4EY

Date: 6 August 2024

YORK AGAINST CANCER
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
AND INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2023

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2023 £	Year ended 31 Dec 2022 £
Income and endowments from:						
Donations and legacies	2	430,182	-	100	430,282	1,169,842
Other trading activities	3	287,169	-	-	287,169	261,895
Investments	4	46,153	-	-	46,153	36,438
Total		763,504	-	100	763,604	1,468,175
Expenditure on:						
Raising funds	5	321,182	-	-	321,182	259,611
Charitable activities	6	457,120	294,949	20,169	772,238	1,559,969
Total		778,302	294,949	20,169	1,093,420	1,819,580
Net income/(expenditure) before gains on investments		(14,798)	(294,949)	(20,069)	(329,816)	(351,405)
Net (losses)/gains on investments	11	(6,362)	-	-	(6,362)	(29,586)
Net income/(expenditure)		(21,160)	(294,949)	(20,069)	(336,178)	(380,991)
Transfers between funds	16	(37,245)	37,245	-	-	-
Net movement in funds		(58,405)	(257,704)	(20,069)	(336,178)	(380,991)
Reconciliation of funds:						
Total funds brought forward		1,151,686	3,109,980	135,403	4,397,069	4,778,060
Total funds carried forward		£ 1,093,281	£ 2,852,276	£ 115,334	£ 4,060,891	£ 4,397,069

The notes on pages 26 to 36 form part of these financial statements.

YORK AGAINST CANCER
(Registration number: 06884476)

BALANCE SHEET
AS AT 31 DECEMBER 2023

	Note	Charity 2023 £	Consolidated 2023 £	Charity 2022 £	Consolidated 2022 £
FIXED ASSETS					
Tangible Fixed Assets	12	998,691	1,033,276	826,241	866,230
Investments	11	2,987,058	2,987,057	3,516,498	3,516,497
		<hr/>	<hr/>	<hr/>	<hr/>
		3,985,749	4,020,333	4,342,739	4,382,727
CURRENT ASSETS					
Stock		-	65,919	-	60,521
Debtors	13	726,455	583,982	1,043,825	912,677
Cash at Bank and in Hand		487,179	548,880	811,874	863,649
		<hr/>	<hr/>	<hr/>	<hr/>
		1,213,634	1,198,781	1,855,699	1,836,847
CREDITORS: amounts falling due within one year	14	1,014,539	1,078,223	1,055,560	1,091,095
		<hr/>	<hr/>	<hr/>	<hr/>
NET CURRENT ASSETS		199,095	120,558	800,139	745,752
TOTAL ASSETS LESS CURRENT LIABILITIES		4,184,844	4,140,891	5,142,878	5,128,479
CREDITORS: amounts falling due after one year	15	80,000	80,000	731,410	731,410
		<hr/>	<hr/>	<hr/>	<hr/>
NET ASSETS		<u>£ 4,104,844</u>	<u>£ 4,060,891</u>	<u>£ 4,411,468</u>	<u>£ 4,397,069</u>
THE FUNDS OF THE CHARITY					
Unrestricted					
Undesignated	18	1,171,819	1,093,281	1,206,074	1,151,686
Designated	16,18	2,817,691	2,852,276	3,069,991	3,109,980
		<hr/>	<hr/>	<hr/>	<hr/>
Restricted	17,18	115,334	115,334	135,403	135,403
		<hr/>	<hr/>	<hr/>	<hr/>
TOTAL CHARITY FUNDS		<u>£ 4,104,844</u>	<u>£ 4,060,891</u>	<u>£ 4,411,468</u>	<u>£ 4,397,069</u>

Approved by the Trustees on 6 August 2024 and signed on its behalf by:

S B Wearing
Director and Trustee

The notes on pages 26 to 36 form part of these financial statements.

**YORK AGAINST CANCER
CONSOLIDATED CASHFLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Note	2023 £	2022 £
Cash flows from operating activities:			
Net cash used in operating activities	21	(484,244)	(226,911)
Cash flows from investing activities:			
Dividends, interest and rents from investments		46,153	36,438
Purchase of property, plant and equipment		(405,743)	(322,442)
Proceeds from sale of property		5,987	-
Proceeds from sales of investments		1,383,378	1,475,082
Purchase of investments		(860,300)	(944,981)
Net cash provided by investing activities		<u>169,475</u>	<u>244,097</u>
Change in cash and cash equivalents in the reporting period		(314,769)	17,186
Cash and cash equivalents at the beginning of the reporting period		<u>863,649</u>	<u>846,463</u>
Cash and cash equivalents at the end of the reporting period		<u><u>£ 548,880</u></u>	<u><u>£ 863,649</u></u>

The notes on pages 26 to 36 form part of these financial statements.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years or life of lease
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
- Motor vehicles	at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2023. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

2. DONATIONS AND LEGACIES	Unrestricted £	Restricted £	2023 £	2022 £
Donations and grants	185,442	100	185,542	228,697
In Memoriam	22,360	-	22,360	26,509
Legacies	217,380	-	217,380	909,636
Intangible income	5,000	-	5,000	5,000
	£ 430,182	£ 100	£ 430,282	£ 1,169,842

During the year the charity was notified of a potential further legacy income from various estates the timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES	2023 £	2022 £
Fundraising income	129,554	136,121
Subsidiary's non-charitable trading turnover	157,615	125,774
	£ 287,169	£ 261,895

4. INVESTMENTS	2023 £	2022 £
Interest received	5,571	1,210
Dividends received	40,582	35,228
	£ 46,153	£ 36,438

5. ANALYSIS OF RAISING FUNDS	Unrestricted £	Restricted £	2023 £	2022 £
Advertising	7,097	-	7,097	6,639
Fundraising costs	109,013	-	109,013	80,727
Non charitable trading - other costs	140,780	-	140,780	115,039
Non charitable trading - staff costs	43,677	-	43,677	34,601
Non charitable trading - depreciation	5,404	-	5,404	5,405
Investment fees	15,211	-	15,211	17,200
	£ 321,182	£ -	£ 321,182	£ 259,611

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2023 £	2022 £
Research				
Jack Birch Unit	-	-	-	363,262
Clinical Trial Nurses	5,144	-	5,144	152,221
Support and Care				
Leveson Centre - direct	111,384	-	111,384	37,378
Leveson Centre -staff	53,049	-	53,049	-
Leveson Centre - depreciation	56,287	-	56,287	-
Psychology services	16,855	-	16,855	10,805
Complementary therapy	16,212	-	16,212	-
Respite property expenses	29,970	-	29,970	22,653
Minibus running costs - direct	10,311	100	10,411	11,882
Minibus running costs - staff costs	22,602	-	22,602	21,273
Mobile Chemotherapy Unit*	-	20,069	20,069	5,740
Transport - Rapid diagnostics	4,948	-	4,948	7,086
Cancer benefit advice service	160,000	-	160,000	-
Robotic surgery	-	-	-	680,000
One off costs	320	-	320	150
Education				
Education expenses	-	-	-	8,850
	487,082	20,169	507,251	1,321,300
Support costs:				
Staff costs	146,138	-	146,138	154,175
Staff training and travel	4,118	-	4,118	3,666
Rent, service charge and rates	35,885	-	35,885	16,871
Heat and light	4,465	-	4,465	3,756
Repairs and maintenance	132	-	132	1,510
Insurances	5,565	-	5,565	4,318
Printing, stationery and postage	4,271	-	4,271	4,913
Computer expenses	11,342	-	11,342	11,516
Telephone	816	-	816	800
Sundry expenses	8,680	-	8,680	4,176
Gains and losses on fixed assets	(3,332)	-	(3,332)	-
Depreciation	25,061	-	25,061	19,370
	243,141	-	243,141	225,071
Governance costs:				
Audit fees	7,440	-	7,440	4,560
Accountancy fees	7,760	-	7,760	7,400
Legal and professional fees	5,670	-	5,670	-
Bank charges	976	-	976	1,638
	21,846	-	21,846	13,598
Total charitable activities	£ 752,069	£ 20,169	£ 772,238	£ 1,559,969

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

7. NET INCOMING RESOURCES FOR THE YEAR

	2023 £	2022 £
This is stated after charging:		
Depreciation	86,752	24,775
Auditor's remuneration for audit services - charity	7,440	4,560

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

	2023 £	2022 £
Wages and salaries	237,607	185,048
Social security costs	15,396	11,194
Pension costs	8,550	7,602
Recruitment costs	930	3,120
Medical Insurance	2,517	3,085
Sub-contractor costs	6,424	-
	£ 271,424	£ 210,049

The average monthly head count was 10 staff (2022 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects	2	1
Trading	2	1
Management and administration	6	6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £93,271 (2022 - £88,871).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £149,404 (2022 £138,024). Interest of £nil (2022 £nil) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2023 £	2022 £
Turnover	160,310	125,774
Cost of sales	(82,637)	(61,578)
Gross profit	77,673	64,196
Administrative expenses	(107,224)	(93,467)
Operating profit	(29,551)	(29,271)
Profit on ordinary activities before taxation	(29,551)	(29,271)
Taxation	-	-
Profit on ordinary activities after taxation	(29,551)	(29,271)
Amount gifted to York Against Cancer	-	-
Retained (withdrawn from)/within Subsidiary	£ (29,551)	£ (29,271)
Net Assets	£ (43,950)	£ (14,339)

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

11. INVESTMENTS

Consolidated	2023 £	2022 £
Market value at 1 January 2023	3,516,497	4,076,184
Additions at cost	860,300	944,981
Disposals	(1,383,378)	(1,475,082)
Revaluations	(6,362)	(29,586)
Market value at 31 December 2023	<u>£ 2,987,057</u>	<u>£ 3,516,497</u>
Analysis of investments by class:		
Listed investments	<u>£ 2,987,057</u>	<u>£ 3,516,497</u>
The historical cost of the above investments amounts to:	<u>£ 2,710,556</u>	<u>£ 3,196,719</u>

The following material investments are over 5% by value of the investments held

	2023 Market value £	2022 Market value £
Ruffer Charity Assets Trust Account	1,611,882	1,832,547
	<u>£ 1,611,882</u>	<u>£ 1,832,547</u>

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

	Property £	Motor Vehicles £	Equipment £	Charity Total £	Subsidiary - Shop Equipment £	Consolidated Total £
<i>Cost</i>						
At 1 January 2023	799,930	88,451	43,843	932,224	54,048	986,272
Additions in year	246,434	-	10,019	256,453	-	256,453
Disposals in year	-	(26,515)	-	(26,515)	-	(26,515)
At 31 December 2023	<u>1,046,364</u>	<u>61,936</u>	<u>53,862</u>	<u>1,162,162</u>	<u>54,048</u>	<u>1,216,210</u>
<i>Depreciation</i>						
At 1 January 2023	44,125	43,222	18,636	105,983	14,059	120,042
Charge for year	63,641	10,518	7,189	81,348	5,404	86,752
Disposals in year	-	(23,860)	-	(23,860)	-	(23,860)
At 31 December 2023	<u>107,766</u>	<u>29,880</u>	<u>25,825</u>	<u>163,471</u>	<u>19,463</u>	<u>182,934</u>
<i>Net book value</i>						
At 31 December 2023	<u>£ 938,598</u>	<u>£ 32,056</u>	<u>£ 28,037</u>	<u>£ 998,691</u>	<u>£ 34,585</u>	<u>£ 1,033,276</u>
At 31 December 2022	<u>£ 755,805</u>	<u>£ 45,229</u>	<u>£ 25,207</u>	<u>£ 826,241</u>	<u>£ 39,989</u>	<u>£ 866,230</u>

All fixed assets are held for direct charitable purposes in Designated Funds.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

13. DEBTORS	Charity 2023 £	Consolidated 2023 £	Charity 2022 £	Consolidated 2022 £
Amounts owed by subsidiary	149,404	-	138,024	-
Prepayments	34,138	41,069	13,396	20,272
Accrued income	542,913	542,913	892,405	892,405
Other debtors	-	-	-	-
	£ 726,455	£ 583,982	£ 1,043,825	£ 912,677

14. CREDITORS: amounts falling due within one year				
Trade creditors	14,785	24,562	176,204	182,320
Project creditors	891,796	891,796	827,466	827,466
Taxation and social security	6,484	16,656	3,802	4,201
Accruals	98,459	142,194	45,342	74,362
Other creditors	3,015	3,015	2,746	2,746
	£ 1,014,539	£ 1,078,223	£ 1,055,560	£ 1,091,095

15. CREDITORS: amounts falling due after one year				
Project creditors	£ 80,000	£ 80,000	£ 731,410	£ 731,410

16. DESIGNATED FUNDS (consolidated)

Designated Funds - 2023	Balance 01/01/2023 £	Income £	Expenditure £	Transfers £	Balance 31/12/2023 £
Leveson Centre	553,750	-	(60,750)	(250,000)	243,000
On demand services	66,000	-	(36,780)	36,780	66,000
Education Project	10,000	-	-	-	10,000
Health Welfare	114,000	-	(114,000)	-	-
Jack Birch Unit	1,500,000	-	-	-	1,500,000
Robotic Surgery Project	-	-	-	-	-
Fixed Assets Fund	866,230	-	(83,419)	250,465	1,033,276
Total	£ 3,109,980	£ -	£ (294,949)	£ 37,245	£ 2,852,276

Designated Funds - 2022	Balance 01/01/2022 £	Income £	Expenditure £	Transfers £	Balance 31/12/2022 £
Leveson Centre	466,500	-	-	87,250	553,750
On demand services	10,000	-	(7,086)	63,086	66,000
Education Project	-	-	(8,850)	18,850	10,000
Minibus	36,000	-	-	(36,000)	-
Health Welfare	-	-	-	114,000	114,000
Jack Birch Unit	-	-	-	1,500,000	1,500,000
Robotic Surgery Project	680,000	-	-	(680,000)	-
Fixed Assets Fund	405,171	-	(24,775)	485,834	866,230
Total	£ 1,597,671	£ -	£ (40,711)	£ 1,553,020	£ 3,109,980

Leveson Centre

The charity has set aside the remaining budget for improvements relating to the Leveson Centre as the year end and 5 years of lease costs.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

16. DESIGNATED FUNDS (consolidated continued)

On demand services

The trustees have set aside monies to fund the following on demand services - patient travel for rapid diagnostics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Minibus

The trustees have set aside monies for the purchase of a new minibus which was purchased in 2022.

Health Welfare

The board wish to fund an additional health welfare post for 3 years in the York area and have ring fenced the following monies.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in 2024 and the trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2024.

Robotic Surgery Project

During the year the charity committed to support the NHS regarding its Robotic Surgery facilities. The commitment of £680,000 has been recognised in 2022 and will be paid over 3 years.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2023	Balance 01/01/2023 £	Income £	Expenditure £	Transfers £	Balance 31/12/2023 £
Mobile Chemotherapy Unit	133,726	-	(20,069)	-	113,657
Minibus Appeal	-	100	(100)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2023	£ 135,403	£ 100	(£ 20,169)	£ -	£ 115,334

Restricted Funds - 2022	Balance 01/01/2022 £	Income £	Expenditure £	Transfers £	Balance 31/12/2022 £
Mobile Chemotherapy Unit	136,966	2,500	(5,740)	-	133,726
Minibus Appeal	-	2,500	-	(2,500)	-
Jack Birch Unit	-	10,000	(10,000)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2022	£ 138,643	£ 15,000	(£ 15,740)	(£ 2,500)	£ 135,403

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Minibus Appeal

Monies were received for the running costs of the minibus in 2023 and the purchase of the new minibus which was in 2022.

Jack Birch Unit

Monies were received for support of the Jack Birch Unit which were used during 2022.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Funds £	Designated Funds £	Restricted Funds £	Total 2023 £
Fund balances at 31 December 2023 are represented by:				
Tangible fixed assets	-	1,033,276	-	1,033,276
Investments	1,487,057	1,500,000	-	2,987,057
Current assets	764,447	319,000	115,334	1,198,781
Current liabilities	(1,078,223)	-	-	(1,078,223)
Long term liabilities	(80,000)	-	-	(80,000)
	£ 1,093,281	£ 2,852,276	£ 115,334	£ 4,060,891
	General Funds £	Designated Funds £	Restricted Funds £	Total 2022 £
Fund balances at 31 December 2022 are represented by:				
Tangible fixed assets	-	866,230	-	866,230
Investments	3,516,497	-	-	3,516,497
Current assets	1,651,698	49,746	135,403	1,836,847
Current liabilities	(1,091,095)	-	-	(1,091,095)
Long term liabilities	(731,410)	-	-	(731,410)
	£ 3,345,690	£ 915,976	£ 135,403	£ 4,397,069

19. OPERATING LEASE COMMITMENTS

As at 31 December 2023 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

	At 31 December 2023		At 31 December 2022	
	Land and buildings £	Office equipment £	Land and buildings £	Office equipment £
Total operating leases payable:				
Within one year	115,905	-	115,905	-
Between two and five years	312,714	-	335,370	-
After five years	210,094	-	278,273	-

20. RELATED PARTIES

During the year the Charitable Company paid £3,182 (2022 £3,097) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2022 £nil) owing to HPH Chartered Accountants.

During 2023 trustees and related parties donated £6,100 (2022 - £116,384) to the charity.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

21. CASH FLOW NOTES

RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES	2023 £	2022 £
Net income/(expenditure) for the reporting period	(336,178)	(380,991)
Adjustments for:		
Depreciation charges	86,752	24,775
Gains on sale of fixed assets	(3,332)	-
(Gains)/Losses on investments	6,362	29,586
Dividends, interest and rents from investments	(46,153)	(36,438)
(Increase)/Decrease in stocks	(5,398)	(5,345)
(Increase)/Decrease in debtors	328,695	(462,906)
Increase/(Decrease) in creditors	(514,992)	604,408
Net cash used in operating activities	£ (484,244)	£ (226,911)
ANALYSIS OF CASH AND CASH EQUIVALENTS		
Cash at bank and in hand	548,880	863,649
Total cash and cash equivalents	£ 548,880	£ 863,649

ANALYSIS OF CHANGES IN NET DEBT

	At 01/01/2023 £	Cash-flows £	At 31/12/2023 £
Cash	863,649	(314,769)	548,880

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

YORK AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

24. COMPARATIVE INFORMATION

	Unrestricted	Designated	Restricted	Year ended
	General	Funds	Funds	31 Dec
	Fund	£	£	2022
	£	£	£	£
Income and endowments from:				
Donations and legacies	1,154,842	-	15,000	1,169,842
Other trading activities	261,895	-	-	261,895
Investments	36,438	-	-	36,438
Total	1,453,175	-	15,000	1,468,175
Expenditure on:				
Raising funds	259,611	-	-	259,611
Charitable activities	1,503,518	40,711	15,740	1,559,969
Total	1,763,129	40,711	15,740	1,819,580
Net expenditure before losses on investments	(309,954)	(40,711)	(740)	(351,405)
Net gains on investments	(29,586)	-	-	(29,586)
Net income/(expenditure)	(339,540)	(40,711)	(740)	(380,991)
Transfers between funds	(1,550,520)	1,553,020	(2,500)	-
Net movement in funds	(1,890,060)	1,512,309	(3,240)	(380,991)
Reconciliation of funds:				
Total funds brought forward	3,041,746	1,597,671	138,643	4,778,060
Total funds carried forward	£ 1,151,686	£ 3,109,980	£ 135,403	£ 4,397,069

25. CAPITAL COMMITMENTS

At the year end the charity was committed to spend £nil (2022- £250,000) for the completion of the Leveson Centre fit out. The Leveson Centre fit out was completed in the year.